Monopar Therapeutics Inc. Made Headway
Thu, Oct 24, 2024 at 07:41 PM
Monopar Therapeutics Inc. (MNPR:NASDAQ) rocketted at $32.66, representing a gain of 605.4%. On Thu, Oct 24, 2024, MNPR:NASDAQ touched a New 2-Week High of $32.66. The stock got featured on our News Catalysts scanner on Thu, Oct 24, 2024 at 08:16 AM in the 'AGREEMENT' category. From Thu, Oct 10, 2024, the stock recorded 40.00% Up Days and 45.45% Green Days
About Monopar Therapeutics Inc. (MNPR:NASDAQ)
Monopar Therapeutics Inc is the United States-based clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. Its pipeline products comprise of Validive, Camsirubicin, and MNPR-101.
Top 10 Gainers:
- Monopar Therapeutics Inc. (MNPR:NASDAQ), 605.4%
- NXU Inc Cl A (NXU:NASDAQ), 138.68%
- Nexalin Technology Inc. (NXL:NASDAQ), 57.51%
- Alpha Technology Group Limited (ATGL:NASDAQ), 52.45%
- Direxion Daily TSLA Bull 2X Shares (TSLL:NASDAQ), 43.73%
- Top Wealth Group Holding Limited (TWG:NASDAQ), 42.11%
- CCSC Technology International Holdings Limited (CCTG:NASDAQ), 38.51%
- Quince Therapeutics Inc Com (QNCX:NASDAQ), 36.78%
- Click Holdings Limited (CLIK:NASDAQ), 36.73%
- Zoomcar Holdings Inc Com (ZCAR:NASDAQ), 31.52%